The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901YOX" target="_blank" >RIV/61988987:17110/18:A1901YOX - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00105233 RIV/65269705:_____/18:00070331 RIV/00843989:_____/18:E0107219

Výsledek na webu

<a href="http://dx.doi.org/10.21873/anticanres.12828" target="_blank" >http://dx.doi.org/10.21873/anticanres.12828</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.12828" target="_blank" >10.21873/anticanres.12828</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma

Popis výsledku v původním jazyce

Background/Aim: Monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma often precede multiple myeloma (MM). The identification of biomarkers predicting progression to MM might facilitate an earlier diagnosis of MM. Our study assessed the diagnostic value of plasma levels of endocan, a 50-kDa soluble dermatan sulfate proteoglycan produced and secreted by endothelial cells, hitherto unknown in MM, in patients with plasma cell dyscrasia. Materials and Methods: Endocan levels were determined in 96 peripheral blood plasma samples by sandwich enzyme-linked immunosorbent assay (ELISA) in healthy controls (n=12), in patients with MGUS (n=17), and in patients newly diagnosed with (n=42) or relapsed/refractory (n=25) MM. Results: Median endocan concentration increased from MGUS (315.00 pg/ml) and healthy controls (316.19 pg/ml) to newly-diagnosed MM (371.82 pg/ml; p=0.027). The low endocan levels (median=246 .20 pg/ml) in patients with relapsed/refractory MM were similar to those in healthy controls and patients with MG US. A cut-off value of >220 pg/ml endocan in peripheral blood discriminated patients newly diagnosed with MM from those with MGUS (area under the curve(AUC)=0.66, 95% confidence interval(CI)=0.55-0.81). Conclusion: The plasma levels of endocan can non-invasively differentiate patients newly diagnosed with MM from those with MGUS and should therefore be evaluated prospectively as a potential diagnostic marker.

Název v anglickém jazyce

The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma

Popis výsledku anglicky

Background/Aim: Monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma often precede multiple myeloma (MM). The identification of biomarkers predicting progression to MM might facilitate an earlier diagnosis of MM. Our study assessed the diagnostic value of plasma levels of endocan, a 50-kDa soluble dermatan sulfate proteoglycan produced and secreted by endothelial cells, hitherto unknown in MM, in patients with plasma cell dyscrasia. Materials and Methods: Endocan levels were determined in 96 peripheral blood plasma samples by sandwich enzyme-linked immunosorbent assay (ELISA) in healthy controls (n=12), in patients with MGUS (n=17), and in patients newly diagnosed with (n=42) or relapsed/refractory (n=25) MM. Results: Median endocan concentration increased from MGUS (315.00 pg/ml) and healthy controls (316.19 pg/ml) to newly-diagnosed MM (371.82 pg/ml; p=0.027). The low endocan levels (median=246 .20 pg/ml) in patients with relapsed/refractory MM were similar to those in healthy controls and patients with MG US. A cut-off value of >220 pg/ml endocan in peripheral blood discriminated patients newly diagnosed with MM from those with MGUS (area under the curve(AUC)=0.66, 95% confidence interval(CI)=0.55-0.81). Conclusion: The plasma levels of endocan can non-invasively differentiate patients newly diagnosed with MM from those with MGUS and should therefore be evaluated prospectively as a potential diagnostic marker.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

38

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

6

Strana od-do

5087-5092

Kód UT WoS článku

000449957600014

EID výsledku v databázi Scopus

2-s2.0-85052985599